Brain tumors, although rare, contribute to distinct mortality and morbidity at all ages.
Although there are few therapeutic options for brain tumors, enhanced biological …

Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the
most difficult cancers to treat in both the primary and recurrent settings. GBM presents a …

Malignant brain tumours are the cause of a disproportionate level of morbidity and mortality
among cancer patients, an unfortunate statistic that has remained constant for decades …

Glioblastoma is the most common and aggressive primary malignant brain tumour. The
prognosis of patients with glioblastoma is poor, and their overall survival averages at 1 year …

Background: Glioblastoma (GBM) is one of the most aggressive types of brain cancer. GBM
progression is closely associated with microglia activation; therefore, understanding the …

ACT001, which is derived from an ancient anti-inflammatory drug, has been shown to cross
the blood-brain barrier in preclinical studies and has demonstrated anti-glioblastoma (GBM) …

Glioblastoma (GBM) is the most common malignant adult brain cancer with no curative
treatment strategy. A significant hurdle in GBM treatment is effective therapeutic delivery to …

Small interfering RNA (siRNA) therapy has been considered as a promising strategy for
treatment of glioblastoma (GBM), which is an aggressive brain disease with poor prognosis …

Simple Summary This paper summarizes the crosstalk between tumor/non-tumor cells and
other elements of the glioblastoma (GB) microenvironment. In tumor pathology, glial cells …

Simple Summary The tumor microenvironment is a complex network comprised of
neoplastic and a variety of immune cells, proteins, and inflammatory mediators. Previous …